Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

OBJECTIVE: To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R., Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010325/
https://www.ncbi.nlm.nih.gov/pubmed/31515290
http://dx.doi.org/10.1212/WNL.0000000000008243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010325/
https://www.ncbi.nlm.nih.gov/pubmed/31515290
http://dx.doi.org/10.1212/WNL.0000000000008243

Ejemplares similares